Side-by-side · Research reference
CagrilintidevsMelanotan-II
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
APhase 3HUMAN-REVIEWED35/64 cited
BPhase 1HUMAN-REVIEWED9/43 cited
01Mechanism of Action
Parameter
Cagrilintide
Melanotan-II
Primary target
Amylin receptor (AMYR) and calcitonin receptor (CTR) heterodimeric complexesBailey 2026
MC1R (skin) + MC3R + MC4R (CNS sexual / appetite)Dorr 1996
Pathway
AMYR/CTR agonism → Central satiety signaling → Reduced food intake, delayed gastric emptying, suppressed glucagonBailey 2026
MC1R agonism → melanocyte tyrosinase → eumelanin synthesis. MC4R → autonomic sexual arousal centresDorr 1996Simerly 2023
Downstream effect
Central satiety induction, prandial glucagon suppression, reduced caloric intake, weight loss, improved glycemic controlBailey 2026Yamauchi 2026
Skin darkening, photo-protection, increased sexual desire / spontaneous erectionDorr 1996
Feedback intact?
Yes — acts via physiological amylin pathways
—
Origin
Second-generation non-aggregating long-acting amylin analogue designed for once-weekly dosingBailey 2026
Cyclic 7-AA modified α-MSH analog; designed at University of ArizonaDorr 1996
Antibody development
—
—
02Dosage Protocols
Parameter
Cagrilintide
Melanotan-II
Standard dose (combination)
Cagrilintide 2.4 mg + Semaglutide 2.4 mg (CagriSema)Yamauchi 2026
Phase 3 REDEFINE 5 trial dosing.
—
Monotherapy dosing
Dose-dependent, under investigation
Monotherapy trials reported in meta-analysis.
—
Frequency
Once weekly (subcutaneous)Bailey 2026
Long-acting formulation.
Daily during loading; 1–2× per week maintenance
Evidence basis
Phase 3 RCT (REDEFINE 5), meta-analysis of 3 RCTs (n=3545)Yamauchi 2026Ahmed 2026
Phase 1 + anecdotalDorr 1996
Maintenance
—
0.5–1.0 mg 1–2×/week
After visible tan develops; supports with UV exposure.
Lower / starter dose
—
0.1 mg / day
Conservative starter — assess tolerability for nausea.
Reconstitution
—
Bacteriostatic water; protect from light
Timing
—
Evening preferred (24h tan-development cycle)
Half-life
—
~1 hour plasma; effects on melanocytes persist days
03Metabolic / Fat Loss Evidence
Parameter
Cagrilintide
Melanotan-II
Weight loss vs semaglutide
7.47% greater percentage weight lossAhmed 2026
CagriSema combination vs semaglutide monotherapy (meta-analysis).
—
Absolute weight change
Significantly greater absolute weight reductionAhmed 2026
Mean difference favoring combination therapy.
—
Glycemic benefit
Reduced fasting glucose and HbA1cAhmed 2026
Synergistic effect with semaglutide in combination.
—
Body composition
Predominant fat loss with weight reduction
—
Mitochondrial function
In vitro effects on skeletal muscle mitochondria under metabolic stress conditionsOld 2026
C2C12 myotube study; clinical relevance under investigation.
—
Key publications
REDEFINE 5 (Yamauchi 2026) · Ahmed meta-analysis 2026 · Bailey review 2026Yamauchi 2026Ahmed 2026Bailey 2026
—
04Side Effects & Safety
Parameter
Cagrilintide
Melanotan-II
Gastrointestinal
Nausea, diarrhea (common with incretin-based therapies)Pardali 2026
Dietary management and nutritional monitoring recommended.
—
Injection site reactions
Local reactions possible with subcutaneous administration
—
Safety profile
Generally consistent with incretin-based therapies
Phase 3 and meta-analysis safety data.
—
Tolerability
Tolerability considerations similar to GLP-1RAs
—
Muscle preservation
Lean mass considerations during weight loss
In vitro mitochondrial effects observed; clinical impact under investigation.
—
Nausea
—
Common, especially loading phase
Flushing
—
Common transient
Increased mole / freckle pigmentation
—
Existing moles darken; new lesions possible
Melanoma risk
—
Theoretical concern — increased melanocyte activity; CAUTION in melanoma history
Appetite suppression
—
MC4R-mediated; mild
Pregnancy / OB
—
Contraindicated
Absolute Contraindications
Cagrilintide
- ·Hypersensitivity to cagrilintide or formulation components
Melanotan-II
- ·History of melanoma or atypical mole syndrome
- ·Pregnancy / breastfeeding
- ·Active uncontrolled hypertension
Relative Contraindications
Cagrilintide
- ·Severe gastrointestinal disease
- ·History of pancreatitis (incretin-based therapy consideration)
Melanotan-II
- ·Significant freckling / dysplastic nevus
- ·Personal or family melanoma history
05Administration Protocol
Parameter
Cagrilintide
Melanotan-II
1. Dosing frequency
Once-weekly subcutaneous injection. Long-acting formulation designed for weekly administration schedule.Bailey 2026
Add 2 mL bacteriostatic water to 10 mg vial → 5 mg/mL = 500 mcg per 0.1 mL. Light-protected.
2. Combination form
Co-formulated with semaglutide as CagriSema for single weekly injection combining amylin and GLP-1 receptor agonism.Yamauchi 2026Bailey 2026
SQ — abdomen. Rotate sites.
3. Injection site
Subcutaneous — typically abdomen, thigh, or upper arm. Rotate injection sites weekly to minimize local reactions.
Evening preferred. UV exposure (sunlight or tanning bed) helps develop tan.
4. Storage
Refrigerate 2–8°C. Follow product-specific storage instructions for pre-filled pens or vials. Protect from light.
Lyophilised: refrigerate, light-protected. Reconstituted: refrigerate ≤30 days.
5. Dietary considerations
Nutritional monitoring recommended during treatment. Dietary management strategies important for tolerability and outcomes.Pardali 2026
29–31G insulin syringe.
06Stack Synergy
Cagrilintide
+ Semaglutide
StrongCagrilintide (amylin receptor agonist) and semaglutide (GLP-1 receptor agonist) act on distinct receptor systems to produce synergistic weight loss through complementary mechanisms — central satiety via amylin pathways plus incretin-mediated glucose control and appetite suppression via GLP-1. Co-formulated as CagriSema, this combination demonstrates 7.5% greater weight loss versus semaglutide monotherapy in Phase 3 trials with additional benefits on glycemic control and lipid parameters.
- CagriSema
- Cagrilintide 2.4 mg + Semaglutide 2.4 mg
- Frequency
- Once weekly subcutaneous
- Duration
- 26–52 weeks (trial data)
- Primary benefit
- Enhanced weight loss, improved glycemic control, multi-pathway metabolic modulation
Melanotan-II
— no documented stacks